Bernard CHARLÈS has been working as the CEO of Dassault Systèmes since 1995 and as Chairman & Chief Executive Officer since 2016. He started his career in the company in 1983 to develop new design technologies. In 1986, he founded a dedicated New Technologies, Research and Strategy department, and in 1988 was appointed President of Strategy, Research and Development.
CHARLÈS has helped instill a culture of ongoing innovation to further consolidate Dassault Systèmes’ scientific capabilities and make science part of the company’s DNA. The inspiration behind digital mock-up, product lifecycle management and 3DEXPERIENCE®, he firmly believes that virtual technology is about making possible the impossible: 3DEXPERIENCE universes are the most powerful vehicle for testing concepts and creating the future, bringing dream and reality together, and stretching the limits of science and imagination to drive progress in society.
CHARLÈS has positioned Dassault Systèmes as the preferred partner for sustainable innovation in three major sectors of the economy: Manufacturing Industries, Life Sciences & Healthcare, Infrastructure & Cities. The company, established in 1981 and world leader in virtual worlds, was recognized as one of Forbes’ "World’s Most Innovative Companies".
Bernard CHARLÈS is a foreign member of the US National Academy of engineering and a member of the French Academy of Technology. He holds the rank of Commander in the “Légion d’honneur” (French Legion of Honor). He is a graduate of the Ecole Normale Supérieure engineering school in Cachan and has a PhD in mechanical engineering majoring in automation engineering and information science. He also holds an agrégation — the most senior teaching qualification achievable in France (specializing in mechanical engineering).
Patrick JOHNSON is SrVP Corporate Science & Research at Dassault Systèmes. His mission is to define the scientific bases of the company’s solutions and invent disruptive technologies for the Industry Renaissance.
After joining in 1996, he held various positions in R&D, from Product Lifecycle Management foundations to product design for the CATIA flagship brand. In 2001, leading the Artificial Intelligence department, he contributed to important new practices now adopted in the industry for knowledge & know-how capture and automation.
Head of Research in 2004, he initiated many strategic technologies, resulting in key innovative products and patents and significantly grew the innovation ecosystem promoting multiple public/private partnerships with prestigious research institutes.
Finally, he launched a new diversification field for the company, with the BioIntelligence European research program, resulting in an innovative modeling, simulation and big data application suite for the life sciences sector, and the creation of the BIOVIA brand.
Mr. Johnson is based at 3DS world headquarters near Paris and is a member of the National Academy of Technology as well as of the scientific board of INRIA.
Alexander POLONSKY is the Vice-President of Research and a co-founder at Bloom. Alexander began the design of Bloom models and algorithms as a Research Scientist in the Artificial Intelligence Lab at EPFL. He had studied neuroscience and applied mathematics at MIT and Stanford, where he obtained his PhD. He has also held positions as a postdoctoral fellow in bioinformatics at Institut Pasteur, Research Manager of a semantic technology startup Mondeca, as well as the CEO/Founder of a content management startup Cognium Systems.
Jérôme ROBERT is a Medical Doctor, certified in Internal medicine and infectious diseases. He is the head of the Bacteriology and Hygiene department of Pitié-Salpêtrière University hospital. He obtained a Master of Public Health degree from the Johns Hospkins School of Public Health, USA, a PhD degree in Epidemiology from Sorbonne University, France.
He is currently Director of the National Reference Centre for Mycobacteria and resistance to antituberculosis drugs, and coordinate the Scientific Board of the national observatory of Bacterial Resistance to antibiotics.
His main research is focused on drug resistant bacteria and their transmission as well as infection control. More recently, he is co-principal investigator in the consortium PRISMES, representing Assistance Publique des Hôpitaux de Paris (APHP). This consortium, awarded by BPI-France in 2021, gathers APHP, Dassault-Systems, ONERA and the Technical University of Compiègne (UTC) in order to decipher the aerosol transmission of pathogens in healthcare settings.
As a graduate of the École des Mines d'Alès and a Paris business school of an MBA holder, Jean Patrick LAJONCHERE, 66, is currently general manager of the Paris Saint-Joseph and Marie-Lannelongue hospital group, an 800 beds private hospital working for public interest located in the 14th arrondissement of Paris and at Plessis-Robinson, since January 2020.
He also had the opportunity to manage the Louis-Mourier hospitals in Colombes and the Saint-Louis in Paris, and then the AP-HP Eastern Parisian university hospital group which includes the Pitié-Salpêtrière, Tenon, Saint-Antoine, Armand-Trousseau, Joffre-Dupuytren, Charles-Foix hospitals and home Hospitalization services. Responsible for the management of Clinical Research Hospital Programs at the French Ministry of Health from 1994 to 1995, he then managed the technical equipment strategy for all the Parisians hospitals within the AP- HP Medical Policy directorate.
Between 1979 and 1994, he worked as a hospital engineer at AP-HP in Cochin, Hôtel Dieu, Saint-Louis and in Vienne (Isère). He is an honorary adjunct professor at the Rennes Faculty of Economic Sciences and Deputy Director of the Master in Economics and Management of Sanitary and Social Establishments.
He was assigned by the regional health agency in 2011 to open the Sud Francilien new hospital. In 2016, Jean Patrick LAJONCHERE was appointed by the French Ministry of foreign affairs to be the new Senior Advisor for the Healthcare business sector. He has been a corresponding member of the French National Academy of Medicine since June 2019.
Alain FISCHER obtained his medical degree (pediatrics) in 1979, he became a professor of immunology at Paris Descartes University, then in 1991 director of an INSERM unit "Normal and pathological development of the immune system". He was head of the "Pediatric Immunology and Hematology" unit (UIH) at the Necker Hospital (AP-HP) from 1996 to 2012. In November 2002, he was elected a full member of the Academy of Sciences and in 2011 of the Academy of Medicine. He was a member of the National Consultative Ethics Committee from 2003 to 2009. He was the co-founding of the Imagine Institute for Genetic Diseases and its director (2007-2016). Alain Fischer was elected as a foreign member of the U.S. National Academy of Medicine in 2017 and of the U.S. Academy of Sciences in 2019. Alain FISCHER is an emeritus professor at the Collège de France, Chair of Experimental Medicine. He was the President of the strategic committee on the french vaccination programme against Covid 2020-2022)
His work has been recognized by numerous awards, including the Jeantet Prize (2001), the INSERM Grand Prix (2008), the Robert Koch Prize (2014), the Japan Prize (2015).
Alain FISCHER's work has been devoted to the study of the human immune system through the characterization of numerous genetic defects and the understanding of their physiopathology. He is the pioneer of gene therapy since 1999.
Eddie REILLY is Head of Global Regulatory Affairs and Chief Regulatory Officer for Sanofi.
In his role, Eddie is responsible for oversight and accountability across Sanofi for Regulatory Affairs activities.
A qualified pharmacist, with a postgraduate degree in Pharmaceutical Medicine, Eddie has also worked in hospital and retail pharmacy and as a pharmaceutical assessor with the Irish Medicines Board (now the HPRA) in Dublin, Ireland before transitioning to Industry.
Spanning more than 20 years in the Pharmaceutical Industry, predominantly in the area of Regulatory Affairs, Eddie has held global positions at both Novartis Vaccines and GSK Biologics prior to joining Sanofi.
Located in Paris, Eddie has been in his current position since January 2020.
Bruno PODDEVIN is the Vice-President Business and Corporate Development at DNA Script. DNA Script is revolutionizing DNA synthesis using enzymatic rather than chemical reactions. DNA Script introduced last year the world’s first benchtop DNA printer powered by enzymatic technology. With a Master in Engineering and a Ph.D. in Molecular Biology, Bruno PODDEVIN spent all his professional career in the synthetic DNA industry, having held responsibilities in most of the pioneering DNA synthesis companies including Genset Oligos, Operon Biotechnologies, MWG Biotech, Sigma Genosys and Proligo.
Over the 15 past years, before joining DNA Script, he initiated and managed the Genomic Services branch of global bio-analytical leader Eurofins, where he helped translating DNA-based technologies into business applications serving a broad range of market segments including food, environment and pharma testing, clinical genetic testing as well as agro- and forensic sciences.